The study was called PROTECT -- and even when compared to a placebo -- Merck's drug candidate rolofylline, um. . . didn't.
Per Yahoo! News:
. . . .Merck said its heart failure treatment rolofylline missed its goals in a trial, failing to improve patient symptoms compared with a placebo. . . .
The medicine failed to meet the primary or secondary efficacy goals in the 2,033-patient Phase III study. . . .
The Whitehouse Station, N.J., company says rolofylline did not reach its primary or secondary goals in the late-stage trial. . . .
And so it goes -- being joined at the hip is not always a good thing.
No comments:
Post a Comment